ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4

ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4
Magnify ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4Enlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Golgi apparatus membrane
TopologyGolgi lumenal side
cytoplasmic side
ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4 » Long-chain acyl-CoA synthetase 4;LACS 4;
Hydrophobic Thickness 30.8 ± 0.8 Å
Tilt Angle 52 ± 0°
ΔGtransfer -25.3 kcal/mol
ΔGfold -17.1 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC, HMDB
Topology Out
TM Segments 7-36 (7-38)
Pathways

γ-linolenate biosynthesis II (animals) (BioCyc)

Adipocytokine signaling pathway (KEGG)

eicosapentaenoate biosynthesis II (metazoa) (BioCyc)

fatty acid α-oxidation II (BioCyc)

fatty acid α-oxidation III (BioCyc)

fatty acid β-oxidation I (BioCyc)

fatty acid β-oxidation VI (peroxisome) (BioCyc)

fatty acid activation (BioCyc)

Fatty acid metabolism (KEGG)

Peroxisome (KEGG)

PPAR signaling pathway (KEGG)

stearate biosynthesis I (animals) (BioCyc)

PDB none
OPM none
Complexes none
Interactions

A4, Complex: ACSL4:A4, PubMed

ACSL3, Complex: ACSL4:ACSL3, PubMed

MOS1, Complex: MOS1:ACSL4, PubMed

Domains

AA: 102-578, PDBID: 2VZE, Subunit A, Seq Identity:26%, AMP-binding enzyme

UniProt annotation for ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4
FUNCTION: Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.

CATALYTIC ACTIVITY: ATP + a long-chain fatty acid + CoA = AMP + diphosphate + an acyl-CoA.

DISEASE: Mental retardation, X-linked 63 (MRX63) OMIM: A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non- syndromic X-linked mental retardation, while syndromic mental retardation presents with associated physical, neurological and/or psychiatric manifestations. Note=The disease is caused by mutations affecting the gene represented in this entry.

DISEASE: Alport syndrome with mental retardation, midface hypoplasia and elliptocytosis (ATS-MR) OMIM: A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, sensorineural hearing loss, mental retardation, midface hypoplasia and elliptocytosis. Note=The gene represented in this entry may be involved in disease pathogenesis.

UniProt features for ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4
CHAIN 1 711 Long-chain-fatty-acid--CoA ligase 4.
Amino Acid Sequence for ACSL4_HUMAN » Long-chain-fatty-acid--CoA ligase 4
MKLKLNVLTI ILLPVHLLIT IYSALIFIPW YFLTNAKKKN AMAKRIKAKP TSDKPGSPYR SVTHFDSLAV IDIPGADTLD KLFDHAVSKF GKKDSLGTRE ILSEENEMQP NGKVFKKLIL GNYKWMNYLE VNRRVNNFGS GLTALGLKPK NTIAIFCETR AEWMIAAQTC FKYNFPLVTL YATLGKEAVV HGLNESEASY LITSVELLES KLKTALLDIS CVKHIIYVDN KAINKAEYPE GFEIHSMQSV EELGSNPENL GIPPSRPTPS DMAIVMYTSG STGRPKGVMM HHSNLIAGMT GQCERIPGLG PKDTYIGYLP LAHVLELTAE ISCFTYGCRI GYSSPLTLSD QSSKIKKGSK GDCTVLKPTL MAAVPEIMDR IYKNVMSKVQ EMNYIQKTLF KIGYDYKLEQ IKKGYDAPLC NLLLFKKVKA LLGGNVRMML SGGAPLSPQT HRFMNVCFCC PIGQGYGLTE SCGAGTVTEV TDYTTGRVGA PLICCEIKLK DWQEGGYTIN DKPNPRGEIV IGGQNISMGY FKNEEKTAED YSVDENGQRW FCTGDIGEFH PDGCLQIIDR KKDLVKLQAG EYVSLGKVEA ALKNCPLIDN ICAFAKSDQS YVISFVVPNQ KRLTLLAQQK GVEGTWVDIC NNPAMEAEIL KEIREAANAM KLERFEIPIK VRLSPEPWTP ETGLVTDAFK LKRKELRNHY LKDIERMYGG K